, Volume 27, Issue 3, pp 210–231


A Review of its Pharmacodynamic Properties and Therapeutic Efficacy
  • D. M. Richards
  • R. N. Brogden
  • R. C. Heel
  • T. M. Speight
  • G. S. Avery
Drug Evaluations


Synopsis: Oxatomide1 is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in a few studies of chronic urticaria and allergic rhinitis. Interestingly, some patients responding to oxatomide were said to be unresponsive to previously administered antihistamines. The effect of oxatomide was little different from placebo in clinical trials of bronchial asthma in adults. While somewhat more encouraging results have been reported in children with bronchial asthma when higher than presently recommended dosages were employed, and in follicular conjunctivitis, atopic dermatitis and food allergy, reports to date are largely preliminary in nature and additional well-controlled studies are needed to clarify the efficacy of oxatomide in such conditions. The drug has been generally well tolerated, but shares some of the familiar H1-histamine receptor antagonist side effects. As with other similarly acting drugs, the 2 primary side effects with oxatomide are drowsiness and weight gain. Thus, on the basis of present evidence, a trial with oxatomide seems a potentially useful alternative in patients with conditions known or thought to be allergic in nature, in whom more established treatments were ineffective or poorly tolerated.

Pharmacodynamic Studies: Oxatomide, an H1-histamine receptor antagonist chemically related to cinnarizine, has demonstrated potent antihistamine activity, some anti-serotonin and anticholinergic activity, and possibly anti-SRS-A activity in several in vitro and in vivo models. Additionally, oxatomide has shown an inhibitory effect on the antigen and chemically mediated release of histamine from rat peritoneal mast cells, human lung tissue, and human basophilic leucocytes, and has attenuated the characteristic mast cell morphology changes associated with anaphylaxis in guinea-pigs and rats. However, the relative contribution of the inhibition of mediator release, versus the antagonism of mediators, to the drug’s observed antiallergic activity in vitro and in vivo (including exercise provocation studies in asthmatic patients) and to its clinical activity is unknown. Additionally, the mechanism by which oxatomide affects the histamine flux from mast cells is also unclear. However, it does not appear to be similar to the mechanism of action of sodium cromoglycate (cromolyn sodium), and probably more closely resembles the mechanism by which some other lipophilic H1-histamine receptor antagonists affect histamine flux in in vitro models of human mast cells. H1-histamine receptors are probably not involved, but there is some evidence to suggest that adsorption of oxatomide into the mast cell cellular membrane and a disruption of calcium movement into the cell are part of the process.

Pharmacokinetics: Peak plasma concentrations occur within 4 hours of administration of an oral oxatomide dose of 60 or 120mg. With long term administration of 30mg twice daily, the mean plasma concentrations increased gradually for about a week and then varied little with continued therapy. Mean monthly plasma concentrations, associated with long term administration of 60mg 3 times daily, remained constant for treatment periods of up to 6 months. A clear correlation was not demonstrated between oxatomide dose and plasma concentration — possibly a reflection of variations in absorption or, more likely, problems with current assay methods.

Oxatomide is highly bound to plasma proteins in human blood (91%). In experimental animals the drug is widely distributed, with highest drug concentrations occurring in the liver, lung and pancreas. Oxatomide also entered the breast milk in lactating beagle dogs, reaching peak milk concentrations of about one-half the peak concentrations in serum.

An elimination half-life of approximately 14 hours was observed following a single 120mg dose of oxatomide in healthy subjects. The drug is extensively metabolised via aromatic hydroxylation and oxidative-N-dealkylation in man, with approximately 40% and 54% of an administered dose excreted as urinary and faecal metabolites, respectively. Less than 0.1% of a dose is excreted in the urine as unchanged drug.

Therapeutic Trials: In placebo-controlled trials in patients with chronic urticaria, oxatomide therapy decreased symptom severity and supplemental antihistamine use, and improved global assessments. Comparative studies demonstrated that oxatomide was as effective as chlorpheniramine and clemastine, and somewhat more efficacious than the phenothiazine antihistamine mequitazine.

In placebo-controlled trials in allergic rhinitis, oxatomide improved symptoms and decreased supplemental antihistamine use. Oxatomide has been shown to be at least as effective as chlorpheniramine, diphenhydramine or the combination of cinnarizine and phenylpropanolamine. Thus, oxatomide is an additional option in patients with allergic rhinitis who do not respond to, or tolerate poorly, these more established antihistamines.

In placebo-controlled trials in adults having bronchial asthma, the activity of oxatomide was little different from that of placebo. A few unpublished studies have reported more encouraging results in children than those in adults when dosages higher than those presently recommended were employed, but further study is needed to clarify whether oxatomide offers a useful alternative in childhood asthma.

Encouraging preliminary results have also been obtained in follicular conjunctivitis, atopic dermatitis and food allergy.

Side Effects: Oxatomide has been generally well tolerated. In common with other H1-histamine receptor antagonists, drowsiness is the most frequent complaint. Weight gain, headache, gastrointestinal complaints, rash and dry mouth have also been reported. In the limited clinical experience reported to date only a few patients have discontinued therapy due to side effects.

Dosage and Administration: The recommended oral dosage is 30mg taken after breakfast and the evening meal. In children, correct dosage is more easily achieved with use of the oral drops in a dosage of 0.5 mg/kg twice daily (which can be doubled if there is insufficient response within a week).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahonen, A.; Muittari, A. and Sovijärvi, A.R.A.: Oxatomide, a new oral antiallergic drug in the treatment of asthma. Current Therapeutic Research 26: 82–88 (1979).Google Scholar
  2. Awouters, F.; Borgers, M.; DeClerck, F. and Niemegeers, C.J.E.: Oxatomide: Comparative experimental studies with other antiallergic agents. International Journal on Tissue Reactions 1: 95–101 (1979).Google Scholar
  3. Awouters, F.; Niemegeers, C.J.E. and Janssen, P.A.J.: Oxatomide: The prototype of a chemical series of compounds inhibiting both the release and the effects of allergic mediators; in Temple, D.L. (Ed.) Drugs Affecting the Respiratory System, pp. 179–208 (American Chemical Society Symposium Series, 1980).CrossRefGoogle Scholar
  4. Awouters, F.; Niemegeers, C.J.E. and Janssen, P.A.J.: Inhibitors of mast cell-mediated shock in the rat: Relationship to histamine and serotonin antagonism. Drug Development Research 1: 107–114 (1981).CrossRefGoogle Scholar
  5. Banham, S.W. and Moran, F.: A clinical trial of oxatomide in asthma. British Journal of Clinical Practice 34: 323–326 (1980).PubMedGoogle Scholar
  6. Bierman, C.W.; Assem, E.S.K. and Mongar, J.L.: Inhibition and stimulation of histamine release by oxatomide. International Journal of Immunopharmacology 1: 227–231 (1979).PubMedCrossRefGoogle Scholar
  7. Blockeel, J. and Leuridan, O.: Oxatomide effects in follicular conjunctivitis of presumed allergic cause: A double-blind evaluation. Ophthamologica 181: 133–138 (1980).CrossRefGoogle Scholar
  8. Borgers, M.; DeBrabander, M.; VanReempts, J.; Awouters, F. and Janssen, P.A.J.: Morphological evaluation of oxatomide — a new anti-allergic drug in guinea pig anaphylaxis. International Archives of Allergy and Applied Immunology 56: 507–516 (1978).PubMedCrossRefGoogle Scholar
  9. Borum, P.: Reactivity of the nasal mucosa; in Pepys, J. and Edwards, A.M. (Ed.) The Mast Cell, pp. 761–766 (Pittman Medical, Kent 1979).Google Scholar
  10. Brogden, R.N.; Speight, T.M. and Avery, G.S.: Sodium cromoglycate (cromolyn sodium): A review of its mode of action, pharmacology, therapeutic efficacy and use. Drugs 7: 164–282 (1974).PubMedCrossRefGoogle Scholar
  11. Church, M.K.: Cromoglycate-like anti-allergic drugs: A review. Drugs of Today 14: 281–341 (1978).Google Scholar
  12. Church, M.K. and Gradidge, C.F.: Oxatomide: Inhibition and stimulation of histamine release from human lung and leucocytes in vitro. Agents and Actions 10: 4–7 (1980a).PubMedCrossRefGoogle Scholar
  13. Church, M.K. and Gradidge, C.F.: Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. British Journal of Pharmacology 69: 663–667 (1980b).PubMedCrossRefGoogle Scholar
  14. DeBeule, R.; Vannieuwenhuyse, E.; Callier, J.; Verstraete, W.; Degreef, F.; Gregoire, M.; Robience, Y.; Stevens, W. and Libert, P.: Double-blind placebo-controlled clinical evaluation of oxatomide (R35443). A novel potent anti-allergic drug in the treatment of hay fever. Acta Allergologica 32: 278–289 (1977).PubMedGoogle Scholar
  15. DeClerck, F.; VanGorp, L.; Vanparijs, O.; Borgers, M. and Awouters, F.: Oxatomide protects Trichinella spiralis infected mice from lethal anaphylaxis. Agents and Actions 8: 568–571 (1978).PubMedCrossRefGoogle Scholar
  16. DeClerck, F.; VanReempts, J. and Borgers, M.: Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells. Agents and Actions 11: 184–192 (1981).PubMedCrossRefGoogle Scholar
  17. DeCree, J.; Verhaegen, H.; Geukens, H. and Streumer, J.: Exercise-induced asthma. The comparative acute effects of oxatomide, placebo and sodium cromoglycate. Clinical Trials Journal 17: 84–91 (1980a).Google Scholar
  18. DeCree, J.; Hörig, C. and Verhaegen, H.: Oxatomide in the treatment of various allergic diseases. Current Medical Research and Opinion 6: 380–385 (1980b).PubMedCrossRefGoogle Scholar
  19. Demaubeuge, J.; Tennstedt, D. and Broux, R.: Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistamine in the treatment of chronic urticaria? Dermatologica 164: 386–394 (1982).PubMedCrossRefGoogle Scholar
  20. Dockx, P.; Vertommen, J.; VanDaele, R.; DeWeert, J. and Amery, W.: Oxatomide effective in chronic urticaria: A double-blind comparison with a placebo. Current Therapeutic Research 29: 510–515 (1981).Google Scholar
  21. Douglas, W.W.: Histamine and 5-hydroxytryptamine (serotonin) and their antagonists; in Gilman, A.G.; Goodman, L.S. and Gilman, A. (Ed.) The Pharmacological Basis of Therapeutics (6th ed.) pp. 609–646 (MacMillan Publishing, New York 1980).Google Scholar
  22. Emanuel, M.B. and Towse, G.D.W.: Oxatomide. A new drug combining antiallergic and antispasmogenic properties. Part I: Pharmacological studies. Drugs of Today 16: 219–229 (1980a).Google Scholar
  23. Emanuel, M.B. and Towse, G.D.W.: Oxatomide. A new drug combining anti-allergic and anti-spasmogenic properties. Part II: Clinical studies. Drugs of Today 16: 231–237 (1980b).Google Scholar
  24. Friedman, H.: Immunologic techniques with pharmacologic application; in Siegler, P.E. and Moyer, J.H. III (Ed.) Animal and Clinical Pharmacologic Techniques in Drug Evaluation, Vol. II pp. 548–568 (Year Book Medical Publishers, Chicago 1967).Google Scholar
  25. Gatti, S.; Coutts, A.; Francis, D. and Greaves, M.W.: Oxatomide: In vitro assessment of antagonistic activity, and effects on histamine release and enzymatic histamine degradation in skin. British Journal of Dermatology 103: 671–677 (1980).PubMedCrossRefGoogle Scholar
  26. Halpern, G.M.; Levy, C.; Benveniste, P. and Levy A.: Treatment of chronic urticaria. Medecine et Hygiene 39: 120 (1981).Google Scholar
  27. Hill, J.S.: Urticaria and angioedema. Postgraduate Medicine 65: 83–90 (1979).PubMedGoogle Scholar
  28. Jackson, R.T.; Per-Lee, J.H.; Burson, J.H. and Turner, J.S.Jr: Ear, nose and throat diseases; in Avery, G.S. (Ed.) Drug Treatment (2nd ed.) pp. 335–361 (ADIS Press, Sydney and New York 1980).Google Scholar
  29. Juniper, E.F.; Cartier, A.; Trebilcock, A.L.; Frith, P.A.; Dolovich, J. and Hargreave, F.E.: Effects of oxatomide compared with chlorpheniramine in allergic rhinoconjunctivitis. Clinical Allergy 11: 61–66 (1981).PubMedCrossRefGoogle Scholar
  30. Lichtenstein, L.M. and Gillespie, E.: Effects of the H1 and H2 antihistamines on “allergic” histamine release and its inhibition by histamine. Journal of Pharmacology and Experimental Therapeutics 192: 441–450 (1975).PubMedGoogle Scholar
  31. Lichtenstein, L.M.; Foreman, J.C.; Conroy, M.C.; Marone, G. and Newball, H.H.: Differences between histamine release from rat mast cells and human basophils and mast cells; in Pepys, J. and Edwards, A.M. (Ed.) The Mast Cell, pp. 83–96 (Pitman Medical, Kent 1979).Google Scholar
  32. Martens, B.P.M.: Some other diagnostic procedures and therapeutic possibilities in food allergy; in Food Allergy pp. 41–45 (hal Allergy Service, Harlem, 1980).Google Scholar
  33. Möller, C. and Björkstén, B.: Oxatomide in seasonal rhinoconjunctivitis. Allergy 35: 319–322 (1980).PubMedCrossRefGoogle Scholar
  34. Monroe, E.W. and Jones, H.E.: Urticaria. An updated review. Archives of Dermatology 113: 80–90 (1977).PubMedCrossRefGoogle Scholar
  35. Nishiyama, S.; Ohkawara, A.; Kishiyama, K. et al.: Clinical evaluation of KW-4354 (Oxatomide), an allergic agent, against chronic urticaria. Hifu 25: 125–140 (1983).Google Scholar
  36. Ohmori, K.; Ishii, H.; Takei, Y.; Shuto, K. and Nakamizo, N.: Pharmacological studies on oxatomide: (3) Effect on experimental asthma and Schultz-Dale response in rats and guinea pigs. Folia Pharmacologica Japonica 80: 481–493 (1982a).PubMedCrossRefGoogle Scholar
  37. Ohmori, K.; Ishii, H.; Shuto, K. and Nakamizo, N.: Pharmacological studies on oxatomide: (4) Effect on the histamine release from rat isolated peritoneal exudate cells (PEC) and lung slices. Folia Pharmacologica Japonica 80: 441–449 (1982b).PubMedCrossRefGoogle Scholar
  38. Ohmori, K.; Ishii, H.; Hirayama, T.; Shuto, K. and Nakamizo, N.: Pharmacological studies on oxatomide (KW-4354): (2) Effect on the experimental models of the type 1-type 4 allergic reactions. Folia Pharmacologica Japonica 80: 261–270 (1982c).PubMedCrossRefGoogle Scholar
  39. Ohmori, K.; Ishii, H.; Shuto, K. and Nakamizo, N.: Pharmacological studies on oxatomide: (6) Effect on peripheral organs. Folia Pharmacologica Japonica 81: 79–104 (1983).PubMedCrossRefGoogle Scholar
  40. Peremans, W.; Mertens, R.L.J.; Morias, J. and Campaert, H.: Oxatomide in the treatment of chronic urticaria: A double-blind placebo-controlled trial. Dermatologica 162: 42–50 (1981).PubMedCrossRefGoogle Scholar
  41. Persico, F.J. and Carpenter, K.: Influence of Oxatomide on Calcium Levels in Rat Mast Cells. Abstract of paper presented to the American Society of Pharmacology and Experimental Therapeutics, Portland (Aug, 1979).Google Scholar
  42. Petheram, I.S.; Bierman, C.W.; Cobley, A. and Spiro, S.G.: Oral prophylaxis of exercise-induced asthma: A study of two new drugs. British Thoracic Association 74: 319–320 (1980).Google Scholar
  43. Playfair, J.H.L.: Anaphylaxis and allergy; in Immunology at a Glance, chapter 27 (Blackwell Scientific, Oxford, London, Edinburgh, Melbourne 1979).Google Scholar
  44. Popa, V.T.: Bronchodilatory activity of an H1-blocker, chlorpheniramine. Journal of Allergy and Clinical Immunology 59: 54–63 (1977).PubMedCrossRefGoogle Scholar
  45. Radermecker, M.: Inhibition of allergen-mediated histamine release from human cells by ketotifen and oxatomide. Respiration 41: 45–55 (1981).PubMedCrossRefGoogle Scholar
  46. Silverman, M. and Tooley, M.: Oxatomide and exercise-induced asthma in children: The value of serial exercise tests. Clinical Allergy 11: 421–428 (1981).PubMedCrossRefGoogle Scholar
  47. Stokes, T.C.; Darbyshire, J.; Nunn, A.J.; Turner-Warwick, M.; Collins, J.V.; Morley, J. and Fox, W.: A controlled trial of oxatomide in the treatment of asthma with or without perennial rhinitis. Clinical Allergy 11: 483–490 (1981).CrossRefGoogle Scholar
  48. Sunaga, Y.; Aoki, H.; Kuwabara, T. et al.: Action of oxatomide on tracheal smooth muscle. Proceedings of 28th Annual Meeting of Japanese Society of Allergology, Kumanoto (Oct, 1978).Google Scholar
  49. Truneh, A.; White, J.R. and Pierce, F.L.: Effect of ketotifen and oxatomide on histamine secretion from mast cells. Agents and Actions 12: 206–209 (1982).PubMedCrossRefGoogle Scholar
  50. Tucker, A.: Pulmonary vascular actions of the antihistamine oxatomide during hypoxia. Agents and Actions 10: 207–212 (1980).PubMedCrossRefGoogle Scholar
  51. Turner-Warwick, M.: On observing patterns of airflow obstruction in chronic asthma. British Journal of Diseases of the Chest 2: 73–86 (1977).CrossRefGoogle Scholar
  52. Van der Bijl, W.J.F.; Cordier, R.; Van Dishoeck, E.A.; De Proost, W. and Vannieuwenhuyse, E.: A double-blind comparison of oxatomide (R35443) and diphenhydramine in the treatment of hay fever. Laryngoscope 90: 145–151 (1980).PubMedCrossRefGoogle Scholar
  53. VanNueten, J.M.; Xhonneux, R. and Janssen, P.A.J.: Preliminary data on antiserotonin effects of oxatomide, a novel antiallergic compound. Archives Internationales de Pharmacodynamie et de Therapie 232: 217–220 (1978).PubMedGoogle Scholar
  54. VanReempts, J.; DeClerck, F. and Borgers, M.: Oxatomide protects against degranulation of rat peritoneal mast cells during in vitro challenge with antigen or compound 48/80. Ultrastructural aspects. Agents and Actions 11: 177–183 (1981).PubMedCrossRefGoogle Scholar
  55. Vannieuwenhuyse, E.; Degreef, F.; DeProost, W. and Callier, J.: Oxatomide in the treatment of chronic allergic rhinitis. Annals of Otology, Rhinology and Laryngology 91: 175–178 (1982).Google Scholar
  56. Verhaegen, H. and DeCree, J.: Treatment of idiopathic chronic urticaria with oxatomide. A placebo-controlled study. Allergologie 3: 30–33 (1980).Google Scholar
  57. Wasserman, S.I.: The mast cell and the inflammatory response; in Pepys, J. and Edwards, A.M. (Ed.) The Mast Cell, pp. 9–19 (Pitman Medical, Kent 1979).Google Scholar
  58. Wihl, J.-Å.: Mast cells in the nasal mucosa; in Pepys, J. and Edwards, A.M. (Ed.) The Mast Cell, pp. 758–760 (Pittman Medical, Kent 1979).Google Scholar
  59. Wood, S.: Oxatomide: A new approach to the treatment of allergic rhinitis. Drugs of Today 18: 341–349 (1982).Google Scholar
  60. Wood, S.F. and Barber, J.H.: Oxatomide in the management of hay fever — a placebo-controlled double-blind study in general practice. Clinical Allergy 11: 491–497 (1981).PubMedCrossRefGoogle Scholar
  61. Zielinski, J. and Chodosowska, E.: Exercise-induced bronchoconstriction in patients with bronchial asthma. Its prevention with an antihistaminic agent. Respiration 34: 31–35 (1977).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1984

Authors and Affiliations

  • D. M. Richards
    • 1
  • R. N. Brogden
    • 1
  • R. C. Heel
    • 1
  • T. M. Speight
    • 1
  • G. S. Avery
    • 1
  1. 1.ADIS Drug Information ServicesBirkenhead, Auckland 10New Zealand

Personalised recommendations